Companies › MNPR
MONOPAR THERAPEUTICS INC (MNPR)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001645469 · EDGAR filings · Updated 2026-07-22
MONOPAR THERAPEUTICS INC (MNPR) has reported institutional ownership of 93.2%, with 81 institutional managers holding positions valued at $341.5M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Filings this week (6)
- 2026-07-22 — S-8 POS filed
- 2026-07-22 — S-8 POS filed
- 2026-07-22 — S-8 POS filed
- 2026-07-22 — S-8 POS filed
- 2026-07-22 — Employee-plan registration (S-8) filed
- 2026-07-22 — Current report (8-K) filed
Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, MONOPAR THERAPEUTICS INC has 81 institutional holders and institutional ownership of 93.2%.
Insider activity
Insiders reported 30 transactions (1 buys, 7 sells) across 9 reporting insiders, with a net reported value of −$38.1M.
Data flags from SEC filings
Related companies
BENITEC BIOPHARMA INC (BNTC) · NEUROGENE INC (NGNE) · PRIME MEDICINE INC (PRME) · AURA BIOSCIENCES INC (AURA) · TENAX THERAPEUTICS INC (TENX) · ENANTA PHARMACEUTICALS INC (ENTA)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-22.